Evidence map›Paper›PMID 25609772›Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2015

Lymphocytes in atherosclerosis.

Catherine C Hedrick

Abstract readReview
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Catherine C HedrickFrom the Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, CA. hedrick@lji.org.

Funding

ROLE OF LIPOXYGENASES IN ATHEROGENESIS IN DIABETES MELLITUSP01HL055798 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HEDRICK, CATHERINE C · 1995 to 2016
$28.4M
ABCG1 Function in DiabetesR01HL085790 · NHLBI · UNIVERSITY OF VIRGINIA · PI HEDRICK, CATHERINE C · 2008 to 2012
$2.9M
T Regulatory Lymphocytes, HDL Function, and AtherosclerosisR01HL112276 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HEDRICK, CATHERINE C, SORCI-THOMAS, MARY G · 2013 to 2016
$2.8M
Lipid Homeostasis, Immunity and AtherosclerosisR01HL097368 · NHLBI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HEDRICK, CATHERINE C · 2011 to 2015
$2.2M
NHLBI NIH HHS P01 HL055798NHLBI NIH HHS R01 HL085790NHLBI NIH HHS R01 HL097368NHLBI NIH HHS R01 HL112276
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunity, InnateAnimalsAtherosclerosisB-Lymphocyte SubsetsHumansInflammation MediatorsKiller Cells, NaturalNatural Killer T-CellsSignal TransductionT-Lymphocyte SubsetsInflammation MediatorsaneurysmatherosclerosisB-lymphocyteskiller cells, naturalnatural killer T-cellsT cells, regulatoryT-lymphocytes

Identifiers

PMID25609772
PMCPMC4327776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.